Systemic Sclerosis With Lung Involvement: Clinical Trials

3 trials for Systemic Sclerosis With Lung Involvement, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 recruiting. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Terminated 2, Recruiting 1

Follow Systemic Sclerosis With Lung Involvement: new trials by email Literature Review of Systemic Sclerosis With Lung Involvement trials Research Report on Systemic Sclerosis With Lung Involvement

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Mycophenolate Mofetil, Placebo - Systemic Sclerosis With Lung Involvement, Systemic Sclerosis
Phase 2RecruitingCentre hospitalier de l'Université de Montréal (CHUM)352024-08-292026-09-29
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Vixarelimab, Placebo - Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Phase 2TerminatedGenentech, Inc.2862023-05-262026-02-09
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
Ixazomib - Systemic Sclerosis, Scleroderma
Phase 2TerminatedMichael M. Pham42021-04-282025-04-06

Narrower conditions

Lung Diseases, Interstitial (2)  ·  Scleroderma, Systemic (2)  ·  Idiopathic Pulmonary Fibrosis (1)  ·  Pulmonary Fibrosis (1)  ·  Scleroderma, Diffuse (1)

Broader conditions

Lung Diseases (3)  ·  Respiratory Tract Diseases (3)  ·  Connective Tissue Diseases (2)  ·  Skin Diseases (2)  ·  Skin and Connective Tissue Diseases (2)  ·  Fibrosis (1)  ·  Lung Diseases, Interstitial (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Pulmonary Fibrosis (1)

Interventions

Mycophenolic Acid (1)  ·  ixazomib (1)

Sponsors

Centre hospitalier de l'Université de Montréal (CHUM) (1)  ·  Genentech, Inc. (1)  ·  Michael M. Pham (1)

Countries

Canada (2)  ·  United States (2)  ·  Argentina (1)  ·  Australia (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Chile (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Israel (1)  ·  Italy (1)  ·  Mexico (1)  ·  New Zealand (1)  ·  Poland (1)

Top investigators

Michael Pham, MD (1)  ·  Sabrina Hoa, MD (1)